导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.00% | 591/4773 |
| 近一周 | -2.76% | 3015/5462 |
| 近一月 | -4.53% | 2544/5421 |
| 近一季 | -2.41% | 1239/5209 |
| 近半年 | 3.66% | 883/4920 |
| 近一年 | 17.61% | 518/4366 |
| 近两年 | 79.57% | 812/2954 |
| 近三年 | 48.33% | 563/2253 |
| 成立以来 | 113.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.57% 892/4961 |
18.78% 1345/5312 |
- - |
- - |
| 2025 | 30.91% 1278/4813 |
3.55% 1071/3635 |
3.05% 1181/4076 |
23.29% 1556/4524 |
-0.49% 2514/4813 |
| 2024 | 7.42% 1662/3463 |
-0.26% 1091/2808 |
-2.27% 1166/3014 |
12.06% 2424/3129 |
-1.65% 1782/3463 |
| 2023 | -9.89% 1243/2656 |
5.23% 811/2280 |
-2.81% 679/2385 |
-6.20% 1451/2515 |
-6.07% 1622/2655 |
| 2022 | -16.94% 534/2207 |
-10.42% 397/1919 |
6.34% 720/2016 |
-12.59% 736/2113 |
-0.24% 1581/2208 |
| 2021 | 21.40% 161/1822 |
0.55% 287/1255 |
11.30% 382/1330 |
6.08% 245/1466 |
2.27% 640/1822 |
| 2020 | 34.01% 444/1250 |
-4.01% 334/1028 |
18.51% 333/1067 |
13.30% 328/1164 |
3.97% 880/1184 |
| 2019 | - - |
- - |
- - |
- - |
9.68% 211/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万菱信中证500指数优选增强C VS. 长安沪深300非周期A(740101) |